# US 2026/0043804 A1 · Compositions and methods for plasmapheresis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0043804 A1
- Document ID: US20260043804A1
- Status: Published application
- Kind: A1
- Application number: 19/365,144
- Filed: 2025-10-21
- Published: 2026-02-12
- Earliest claimed: 2022-05-31
- Assignees: Circulate Health, Inc.
- Applicants: Circulate Health, Inc.
- Inventors: Dobri Kiprov
- Web page: https://patentgrep.com/patent/US20260043804A1

## CPC

- G01N 33/56972: {White blood cells}
- A61B 5/0022: {Monitoring a patient using a global network, e.g. telephone networks, internet}
- A61B 5/1118: {Determining activity level}
- A61B 5/1122: {of movement trajectories}
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61M 1/342: {Adding solutions to the blood, e.g. substitution solutions (for preventing coagulation A61M1/3672)}
- A61M 1/3496: {Plasmapheresis; Leucopheresis; Lymphopheresis (A61M1/3472 takes precedence)}
- A61M 1/36: Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation {; Extra-corporeal blood circuits}
- A61M 1/361: {before treatment}
- A61M 1/3612: {after treatment}
- A61M 1/38: Removing constituents from donor blood and {storing or} returning remainder to body {, e.g. for transfusion}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61B 5/1114: {Tracking parts of the body}
- A61M 1/362: {changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity}
- A61M 1/3693: {using separation based on different densities of components, e.g. centrifuging}
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

## Claims

### Claim 1

A method for using plasmapheresis to reduce a level of an inflammatory agent in an individual in need thereof, the method comprising the steps of:
(a) measuring, before administering the plasmapheresis, a pretreatment level of the inflammatory agent in a blood sample of the individual;
(b) administering the plasmapheresis to the individual;
(c) measuring, following step (b), the level of the inflammatory agent in a further blood sample of the individual; and
(d) repeating steps (b) and (c) until the level of the inflammatory agent in the individual reaches a target level.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammatory agent is a molecular agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inflammatory agent is a non-cellular agent.

### Claim 4 (depends on 1)

The method of claim 1, further comprising decreasing the inflammatory agent by 60% to 70% following administering the plasmapheresis in step (b).

### Claim 5 (depends on 1)

The method of claim 1, wherein step (a) occurs within 24 hours of the administering of the plasmapheresis to the individual in step (b).

### Claim 6 (depends on 1)

The method of claim 1, wherein the plasmapheresis administered in step (b) exchanges at least one unit of plasma volume.

### Claim 7 (depends on 1)

The method of claim 1, wherein the plasmapheresis administered in step (b) is administered over a plurality of treatment sessions.

### Claim 8 (depends on 1)

The method of claim 1, wherein the plasmapheresis that is administered in step (b) is administered over a single treatment session.

### Claim 9 (depends on 1)

The method of claim 1, further comprising reducing an inflammation in the subject.

### Claim 10 (depends on 9)

The method of claim 9, further comprising repeating steps (b)-(c) until a specific value is achieved for an improvement in the inflammation.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering an anti-inflammatory agent to the individual.

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering an anti-inflammatory agent to the individual following step (b).

### Claim 13 (depends on 12)

The method of claim 12, wherein the administering the anti-inflammatory agent is administered within 24 hours of administering the plasmapheresis in step (b).

### Claim 14 (depends on 1)

The method of claim 1, further comprising administering intravenous immunoglobulin to the individual.

### Claim 15 (depends on 1)

The method of claim 1, further comprising administering intravenous immunoglobulin to the individual following step (b).

### Claim 16 (depends on 15)

The method of claim 15, wherein the intravenous immunoglobulin is administered within 24 hours of administering the plasmapheresis in step (b).

### Claim 17 (depends on 14)

The method of claim 14, wherein the intravenous immunoglobulin is administered in an amount of about 2 grams per kilogram of a body weight of the individual.

### Claim 18 (depends on 14)

The method of claim 14, wherein the intravenous immunoglobulin is administered during the same treatment session as administering the plasmapheresis in step (b).

### Claim 19 (depends on 1)

The method of claim 1, further comprising performing steps (a)-(d) on the individual at least two times per month for at least three months, wherein two of the at least two times per month are within the same week of the month.

### Claim 20 (depends on 19)

The method of claim 19, wherein the intravenous immunoglobulin is administered to the individual at each of the at least two times per month.
